Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2017
April 2017, Vol 7, No 4
April 2017, Vol 7, No 4
Telemedicine: The Future Is Now
By
Meg Barbor, MPH
Oncology Practice Conference 2017
Telemedicine, or the remote diagnosis and treatment of patients by means of telecommunications technology, is now at the forefront of efficient healthcare delivery. This fundamental change in the delivery of healthcare focuses on bringing medicine to the patient rather than bringing the patient to medicine.
Read More ›
Operational and Cultural Changes in Oncology: Are You Paying Attention to Your Teams?
By
Gail Thompson
Cancer Center Business Summit
Read More ›
Rapid Adoption of Novel Oncology Drugs Improves Overall Survival
By
Chase Doyle
Survivorship
Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health, reported Jason Shafrin, PhD, Director of Healthcare Quality and Value-Based Research Methods, and Senior Research Economist, Precision Health Economics, Los Angeles, CA, who presented the results of a geographic-based analysis of claims data at the 2017 Cancer Survivorship Symposium.
Read More ›
Strategic Planning Under MACRA/MIPS
By
Dawn Holcombe, MBA, FACMPE, ACHE
From the Editor
Read More ›
The Art of Negotiation Critical to Sustaining an Oncology Practice
By
Meg Barbor, MPH
Oncology Practice Conference 2017
Successful negotiations are critical to sustaining a business and retaining key customers, including in oncology practices, suggested Steven L. D’Amato, BSPharm, BCOP, RPh, Executive Director, New England Cancer Specialists, at ASCO’s first Oncology Practice Conference in March 2017.
Read More ›
Making the Transition from Volume to Value
By
Meg Barbor, MPH
Oncology Practice Conference 2017
Value-based care—the best care delivered at the lowest cost—is here to stay, said Karen K. Fields, MD, Medical Director, Clinical Pathways and Value-Based Cancer Care, Moffitt Cancer Center, Tampa, FL, at ASCO’s first Oncology Practice Conference in March 2017.
Read More ›
Clinical Pathways: The Path Forward
By
Meg Barbor, MPH
Oncology Practice Conference 2017
,
Clinical Pathways
Clinical pathways have become a central component of medical oncology practice and a cornerstone of future reimbursement methodologies and quality-of-life efforts, according to Robin Zon, MD, FACP, Medical Oncologist, Michiana Hematology Oncology, IN, and Chair, ASCO Task Force on Clinical Pathways.
Read More ›
FDA News - April 2017
FDA Approvals, News & Updates
Read More ›
Reducing Disparities in Survivorship Care
By
Chase Doyle
Disparities in Cancer Care
Read More ›
Improving Provider Knowledge of Cancer Survivorship Needs and Management Through E-Learning Series
By
Chase Doyle
Survivorship
ith an estimated 15.5 million cancer survivors living in the United States, caring for survivors is becoming an unmet need, suggesting an increased need for continuing education for oncology and primary care providers that is better focused on this growing population and the special needs associated with survivorship.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes